Home / Market News / $ABBV
benzinga Corporate Catalyst Impact 55/100 ● positive

Scotiabank Maintains Sector Outperform on AbbVie, Raises Price Target to $320

Oct 6, 2026, 12:45 PM UTC · Primary ticker $ABBV

Scotiabank analyst Louise Chen has reiterated a 'Sector Outperform' rating for AbbVie and increased its price target from $280 to $320. This indicates a positive outlook from the analyst, suggesting potential upside for the stock.

Scotiabank analyst Louise Chen maintained a 'Sector Outperform' rating on AbbVie and raised the price target from $280 to $320. This action signals continued confidence in AbbVie's performance and future prospects from a prominent financial institution. For traders, this represents a positive short-term catalyst, potentially leading to increased buying interest and upward price movement for ABBV shares. The long-term implication is a reinforced positive sentiment around the company's valuation. The key opportunity for traders is to capitalize on the potential upward momentum driven by this analyst upgrade, though market reaction can vary.

$ABBV positive Analyst price target increase and outperform rating
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.